Article
After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations. Here are a few of the highlights that I saw.
All News
Rheumatology Network
Tweet
Data from the COSMOS study showed that 44.4% of patients who received #guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24. #psoriaticarthritis
https://t.co/S3xnFSQDaJ
Dr. John Cush
Tweet
PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate)
https://t.co/sUXTXDXrFh
Eric Dein
Tweet
#EULAR2021 OP0133 retinal toxicity with HCQ use. ⬆️ risk:
⭐️Duration 10-14.9 yr (OR 5)
⭐️Duration >15 yr (OR 19)
⭐️Dose >7 mg/kg/d (OR 4.6)
⭐️Cum dose >2000 g
Atherosclerosis, age >80 seen in multi-var analysis
But didn't have HCQ levels to predict risk @MaxKonigMD
@RheumNow https://t.co/DzWWm0U64L
Robert B Chao, MD
Tweet
TNFi use associated with ⬇️ radiographic sacroilitis progression in patients with AxSpA
⭐️effect becomes evident between 2 and 4 years after treatment
Abs#OP0137
#EULAR2021 @RheumNow
Robert B Chao, MD
Tweet
Machine learning to model risk for SSc-ILD
⭐️predict time to lung function decline
⭐️needs larger sample size
Abs#OP0150
#EULAR2021 @RheumNow
ARD & RMD Open
Tweet
OP0186 #EULAR2021 by Dr. Mariele Gatto.
Anti-cancer effect of immunotherapy with ICI is believed to be mediated by CD8 positive Tc cells.
It is not known if other cells get activated. This study looks at B cells.
Transitional B cells ⬆️ in ICI induced arthritis (CP-IA).
/TK https://t.co/szFF81SKVL
Dr. Antoni Chan
Tweet
No requirement to stop cDMARDs before surgery. For biologics stop 1 dose before and restart 14 days post op, JAKi stop 7 days before, restart 14 days post op, glucocorticoids >10mg/day increases risk of infection in #rheumatoidarthritis Michael D George #EULAR2021
Paul Studenic
Tweet
#POS0093 Collaborative registry studies are to be encouraged! BUT
@k_lauper outlines the heterogenity between registries concerning #AE reporting - Jak-pot study - 18 registries with #RA patients on #tofacitinib - Rates of discontinuation vary across registry
#EULAR2021 @RheumNow https://t.co/oczJAG8hzv
Meral K. El Ramahi, MD
Tweet
SPACING trial OP0138 at #EULAR2021
⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo)
⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx
⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow
EMEUNET
Tweet
Immune events with #checkpointinhibitors 🧐which are the most common? Interesting talk by Maria Suarez-Almazor at #EULAR2021 @eular_org https://t.co/PFPPL4cqOG
Janet Pope
Tweet
You put a pt on a #Jaki What is most likely infection that will occur? #EULAR2021 @RheumNow @eular_org
David Liew
Tweet
So how do irAEs work?
Dr. Anne Bass @lovetolearn27 @HSpecialSurgery gives #EULAR2021 a possible conceptual framework
@LCalabreseDO @CCalabreseDO @cappelliMD @got_rheum @MarieKostine and so many other good people! @RheumNow https://t.co/5eOZDwkGO6
Aurelie Najm
Tweet
An original way of differentiating RA from PsA!
The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of
-HC 94%
-RA 84%
-PsA 89%
and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310
Eric Dein
Tweet
Presentation 3480 at #EULAR2021. Your patient is on CellCept, has negative COVID spike IgG and IgM antibodies after vaccination with mRNA vaccination x2. What do you counsel on this test? @RheumNow
k dao
Tweet
Anifrolumab pooled TULIP-1&-2 data on rash and arthritis in SLE more effective in pts with high IFN signals (pts with low IFN may benefit, but they had less rash but more arthritis)- Dr. J Merrill #OP0131 #EULAR2021 @rheumnow
Laurent ARNAUD
Tweet
@KDAO2011 @RheumNow @LupusDocLim @Lupusdoc1 @LupusMD Check this! (top left corner)
#HCQ #Lupus #EULAR2021
Link: https://t.co/RQcWoStJtP https://t.co/96l1FvYDQH
k dao
Tweet
⬆️prevalence of HCQ retinopathy: Kaiser Permanente 676 pts retrospect study #OP0133
👉6.8% (n=46) had HCQ retinopathy w/ risks:
👉age>80 (OR 3.83)
👉h/o atherosclerosis (OR 2.99),
👉cum. dose >2000 mg (OR 15.8)
👉10-15 yrs use (OR 4.44)
👉>15 yrs (OR 19)
#EULAR2021 @rheumnow https://t.co/QA8HHXdnjL
Dr. John Cush
Tweet
News: Featured Abstracts from Industry at EULAR 2021
https://t.co/hIBYUdHTLf https://t.co/LTTJ3WPl7X
Eric Dein
Tweet
#EULAR Presentation 3478: Infection risk with surgeries:
⭐️Continue conventional DMARD
⭐️Some risk with biologics, may be confounder and no association with timing of infusions
⭐️Steroids are major risk factor! Esp >10 mg/d
⭐️Recommendations shown
⭐️Address other risks!
@rheumnow https://t.co/Bi02d4p9Mw
